Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness
Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness
复制标题
DOI：
10.15420/ecr.2020.24
复制
发表时间：
2020-01-01
影响因子：
3
通讯作者：
Hasegawa, Koji
中科院分区：
文献类型：
--
作者：
Komiyama, Maki;Hasegawa, Koji
由严重急性呼吸系统综合征冠状病毒2型（SARS-CoV-2）引起的冠状病毒病2019 （COVID-19）已成为全球大流行。SARS-CoV-2与血管紧张素转换酶2受体结合，血管紧张素转换酶2受体在血管内皮细胞中大量表达，并损害这些细胞。除了肺炎引起的呼吸衰竭外，血栓性心血管并发症越来越多地成为COVID-19的主要症状。多项回顾性研究强烈表明，抗凝治疗可改善COVID-19患者的预后。然而，迫切需要验证COVID-19抗凝治疗的安全性和有效性，并提高对这一临床治疗选择的认识。
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. SARS-CoV-2 binds to the angiotensin-converting enzyme 2 receptor, which is abundantly expressed in vascular endothelial cells and damages these cells. Besides pneumonia-induced respiratory failure, thrombotic cardiovascular complications are increasingly emerging as a major COVID-19 symptom. Multiple retrospective studies have strongly suggested that anticoagulant therapy improves the prognosis of people with COVID-19. However, validation of the safety and effectiveness of anticoagulant therapy for COVID-19 and greater awareness of this clinical therapeutic option are urgently needed.